Evgen Pharma PLC Grant of further European patent (8199M)
02 May 2018 - 4:00PM
UK Regulatory
TIDMEVG
RNS Number : 8199M
Evgen Pharma PLC
02 May 2018
For immediate release 2 May 2018
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Grant of further European patent
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce the grant of a key European
patent ascribing intellectual property rights to the Company for a
method of stabilising sulforaphane, the naturally occurring
compound on which SFX-01, the Company's lead product, is based.
The grant of this core patent, which expires on 23 January 2028,
marks another important step in expanding the Company's worldwide
intellectual property estate surrounding sulforaphane and the
Company's synthetic, stabilised version, SFX-01.
This patent represents the Company's second process patent grant
in Europe and follows the announcement of a manufacturing and
scale-up grant in October 2017. Composition-of-matter and
manufacturing patents have already been granted in the USA. Patents
are also granted, or in the process towards being granted, in other
key commercial territories.
The European patent announced today, numbered EP2796140 and
entitled Stablilized Sulforaphane, can be viewed at this link:
https://register.epo.org/application?number=EP14166888&lng=en&tab=main.
Exclusive worldwide rights to the patent are held by Evgen
Pharma under the terms of a licence agreement with PharmAgra Labs
Inc., the US laboratory that invented SFX-01.
In line with Company policy, an update on less material patent
developments, including grants related to the Company's
sulforaphane analogues, will be included as part of the Company's
full year results.
Steve Franklin, CEO of Evgen Pharma, said:
"We are delighted by the grant of this core patent in Europe,
which further expands our intellectual property position and
complements similar grants in the USA, Canada and Australia. This
patent grant is timely from a commercial perspective as we are
moving close to the announcement of our first Phase II clinical
data from SFX-01, which we continue to expect in the first half of
this year as part of our ongoing STEM trial in breast cancer."
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466
Dr Stephen Franklin, CEO 5000
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Stephanie +44 (0) 20 7466
Watson 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney,
Tom Price (Corporate Finance)
John Howes, Rob Rees (Corporate +44 (0) 20 3861
Broking) 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a composition of
synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUGUCUAUPRPGG
(END) Dow Jones Newswires
May 02, 2018 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024